In contrast to KRAS mutant colorectal cancer, where KRAS mutations are predictive of poor response to anti-EGFR monoclonal antibodies, cetuximab and panitumumab, BMS099 and FLEX clinical trials demonstrated no statistically significant association between KRAS status and ORR, PFS, or OS when cetuximab was added to platinum-based chemotherapy in patients with advanced NSCLC [82, 83]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.